Open AccessUbiquitin-specific protease 22 is associated with poor prognosis in neuroblastoma
Author(s) -
Zhipeng Qu,
Lianxin Liu
Publication year - 2020
Publication title -
advances in clinical and experimental medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.486
H-Index - 27
eISSN - 2451-2680
pISSN - 1899-5276
DOI - 10.17219/acem/115089
Subject(s) - immunohistochemistry , tissue microarray , biomarker , clinical significance , medicine , cancer research , pathology , oncology , biology , biochemistry
Ubiquitin-specific protease 22 (USP22) alters histone ubiquitination and is considered to be an oncogenic factor involved in tumor progression. The USP22 aberrance has been implicated in several malignancies, but whether USP22 plays a role in neuroblastoma (NB) remains unclear. To the best of our knowledge, the clinicopathological significance of USP22 expression in NB has not been previously reported in the English-language medical literature.